Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
gastrointestinal tumors
Biotech
Innovent, fresh from $1.2B deal, posts key win for CLDN18.2 ADC
Innovent Biologics has reported a phase 3 victory for IBI343, boosting the prospects of an antibody-drug conjugate that Takeda bet big on last year.
Nick Paul Taylor
Jun 4, 2026 7:47am
At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms
Jun 1, 2026 3:55pm
Agenus focuses on survival data as trial flops with no responses
Apr 20, 2026 5:53am
Cogent eyes FDA approval after clearing another ph. 3 hurdle
Nov 10, 2025 10:57am
Olympus forms GI robotics startup with Revival Healthcare
Jul 25, 2025 11:50am
Astellas aims for CLDN18.2 gold with $1.34B licensing deal
May 29, 2025 7:30pm
